Adult Hematology News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Adult hematology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Adult Hematology Today - Breaking & Trending Today

29.8 mn cancer patients by 2025, ICMR advises utmost care

ICMR report released on World Cancer Day said 29.8 million people could become victim to cancer by 2025 and advised people to take utmost precautions. ....

Sharat Damodar , Mazumdar Shaw Medical Centre , Narayana Health City , Indian Council Of Medical Research , Narayana Health On World Cancer Day , Indian Council , Medical Research , Life Lost , Chairman Oncology Collegium , Narayana Health , World Cancer , Cancer Day , Adult Hematology , North East India , Searchcancer Projections 2025 , Icmr Report , Indian Council Of Medical Research , Hen Is World Cancer Day Observed , Hy Cancer Day Is Observed , Most Common Cancer , Ommon Cancer In Children ,

Cancer projections for 2021-25 show a worrisome figure: Experts

The cancer projections for 2021-2025 show a worrisome figure and are looking at an increase to 29.8 million in 2025 from 26.7 million in 2021, as per the Indian Council of Medical Research (ICMR) report, with men contributing to 14.7 million . ....

Sharat Damodar , Mazumdar Shaw Medical Centre , Narayana Health City , Indian Council Of Medical Research , Narayana Health On World Cancer Day , Indian Council , Medical Research , Life Lost , Chairman Oncology Collegium , Narayana Health , World Cancer , Cancer Day , Adult Hematology , North East India ,

Innate Pharma to Host Key Opinion Leader Discussion on the Potential Role of Lacutamab Across ...

Press release content from Globe Newswire. The AP news staff was not involved in its creation.
Innate Pharma to Host Key Opinion Leader Discussion on the Potential Role of Lacutamab Across .
INNATE PHARMAFebruary 3, 2021 GMT
MARSEILLE, France, Feb. 03, 2021 (GLOBE NEWSWIRE) Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual key opinion leader (KOL) discussion focused on the potential role of its lead investigational drug candidate, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas. The event will be held virtually on Tuesday, February 9, 2021 at 2:00 p.m. CET / 8:00 a.m. ET. ....

Universitaire Necker Enfants Malades , Pierluigi Porcu , Bristol Myers Squibb , Novo Nordisk , Olivier Hermine , Division Of Hematologic Malignancies , University Of Paris Descartes , Division Of Adult Hematology , Exchange Commission , French Financial Markets Authority , Company Annual Report On Form , Member Of The Lymphoma Study Association , Euronext Paris , Medical Oncology , Cutaneous Biology , Hematologic Malignancies , Hematopoietic Stem Cell Transplantation , Thomas Jefferson University , Principal Investigator , Paris Descartes , Adult Hematology , Des Sciences , Lymphoma Study Association , Innate Pharma , Private Securities Litigation Reform Act , Risk Factors ,

Innate Pharma to Host Key Opinion Leader Discussion on the Potential Role of Lacutamab Across T-Cell LymphomasVirtual event to take place at 2:00 p.m. CET / 8:00 a.m. ET on Tuesday, February 9, 2021

Published: Feb 03, 2021
Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“
Innate” or the “
Company”) today announced that it will host a virtual key opinion leader (KOL) discussion focused on the potential role of its lead investigational drug candidate, lacutamab, an anti-KIR3DL2 cytotoxicity-inducing antibody in development for T-cell lymphomas. The event will be held virtually on Tuesday, February 9, 2021 at 2:00 p.m. CET / 8:00 a.m. ET.
The event will feature presentations from the Company’s executive leadership team, as well as the following KOLs:
Pierluigi Porcu, M.D., Professor of Medical Oncology, Dermatology and Cutaneous Biology and Director, Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation at Thomas Jefferson University, US; Principal Investigator of Innate’s Phase 2 TELLOMAK clinical trial, which is evaluating lacutamab in mycosis fungoides and Sézary syndrome; and ....

Universitaire Necker Enfants Malades , Pierluigi Porcu , Bristol Myers Squibb , Novo Nordisk , Olivier Hermine , Division Of Hematologic Malignancies , University Of Paris Descartes , Division Of Adult Hematology , Exchange Commission , French Financial Markets Authority , Company Annual Report On Form , Member Of The Lymphoma Study Association , Euronext Paris , Medical Oncology , Cutaneous Biology , Hematologic Malignancies , Hematopoietic Stem Cell Transplantation , Thomas Jefferson University , Principal Investigator , Paris Descartes , Adult Hematology , Des Sciences , Lymphoma Study Association , Innate Pharma , Private Securities Litigation Reform Act , Risk Factors ,